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S U M M A R Y
Objective: A systematic review of the literature was conducted to summarize the descriptive and
molecular epidemiology of human cases and surveillance reports with New Delhi metallo-b-lactamase
type 1 (NDM-1)-producing bacteria reported worldwide from January 2008 through July 6, 2011.
Methods: A comprehensive literature review was conducted to identify publications of NDM-1-
producing bacteria. Studies were divided into two broad categories of (1) case series and case reports of
NDM-1-producing bacteria, or (2) active surveillance and environmental surveillance studies of NDM-1-
producing bacteria.
Results: Sixty cases with NDM-1-producing bacteria were reported in the 3.5-year interval since the
index case detection. The majority of reported cases represented colonization without evidence of
infection (n = 39, 65%); urine was the most common specimen source for cases with infection (41.7%) and
colonization (33.3%). Seventeen cases (28.3%) had NDM-1-producing bacteria at more than one body
site. Klebsiella pneumoniae and Escherichia coli were the most frequent bacteria detected, and the
multilocus sequence type data from 34 E. coli and K. pneumoniae clinical isolates provided an incomplete,
yet heterogeneous global distribution of NDM-1-producing bacteria. The majority of cases (63.3%) had
exposure to the Indian subcontinent of south central Asia, and laboratory surveillance systems, as well as
an environmental survey from India, suggest a presence of environmental reservoirs for potential human
infection and colonization with NDM-1-producing bacteria.
Conclusions: The majority of case reports with NDM-1-producing bacteria had presumed colonization,
not infection, with one or more bacteria. The available human case reports and surveillance data suggest
a global distribution of NDM-1-producing Enterobacteriaceae and non-Enterobacteriaceae.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Infections with multidrug-resistant Gram-negative bacteria are
of major global concern given limited therapeutic options, untoward
clinical outcomes, and excess costs of care.1,2 Heterogeneous
resistance trends to cephalosporins, ﬂuoroquinolones, and carba-
penems exist among Enterobacteriaceae and non-Enterobacteriaceae,
which add to the complexity of region-speciﬁc effective infection
prevention and treatment strategies. Treatment of carbapenemase-
resistant Enterobacteriaceae (CRE) now includes combination regi-
mens of carbapenems, colistin, aminoglycosides, aztreonam, and
tigecycline, as well as prolonged infusions of carbapenems.3–11
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E-mail address: linda.m.mundy@gsk.com (L.M. Mundy).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.11.025type-1 (NDM-1), produced by the blaNDM-1 gene, utilize at least one
zinc atom at the active site to facilitate hydrolysis of a broad variety
of b-lactams and carbapenems.12 The epidemiology of NDM-1 is
compounded by interspecies dispersion and recognized implica-
tions for patient care, public health, antimicrobial surveillance
programs, and drug development.3,8,13–15
Initial case detection of NDM-1 production was characterized in
a clinical urinary isolate of Klebsiella pneumoniae from a 59-year-
old man who returned to Sweden after hospitalization in India in
January 2008.16 This patient was concurrently colonized with an
NDM-1-producing Escherichia coli in the stool.16 Subsequently, two
NDM-1-producing E. coli strains from 2006 were retrospectively
identiﬁed in stored clinical isolates from healthcare facilities in
New Delhi, India via the SENTRY Antimicrobial Surveillance
Program.17 Since 2008, NDM-1-producing bacteria have been
reported via case detection, active and passive laboratory
surveillance systems, national surveillance programs, andses. Published by Elsevier Ltd. All rights reserved.
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detection of NDM-1 has been in K. pneumoniae and E. coli, with
global spread associated with international travel, medical
tourism, and potential exposures in the Balkan region and the
Indian subcontinent.3,16,18,20,22,24–26 In Europe, a case series of
subjects with NDM-1-producing Enterobacteriaceae has served as a
template for linking clinical and laboratory case detection.7 From
an epidemiological perspective, the global burden of disease
associated with NDM-1-producing pathogens remains underrep-
resented in the literature.3,27 The objective of this systematic
review was to characterize the global distribution of human cases
and surveillance studies for NDM-1-producing bacteria for the 3.5-
year period since the initial case detection.
2. Methods
2.1. Systematic literature review
A comprehensive literature review was conducted using the
PubMed search engine and the following key search terms: ‘‘New
Delhi Metallo-Beta-Lactamase’’ and ‘‘NDM-1’’. Search terms were
limited to publications in the English language, publications in
humans, and literature sources published from January 2008
(month and year of the clinical presentation of the NDM-1 index
case) through July 6, 2011. Articles available through online
advanced access were included and, in order to ascertain any
citations that were not identiﬁed in the original literature search,
relevant publications were examined for additional references to
NDM-1-producing bacteria. Articles with complete text were
analyzed and the relevant data from these publications were
systematically collated into a tabulated format. Articles with only
abstracts were included if the abstract contained sufﬁcient
information to meet the study inclusion criteria. NDM-1 publica-
tions were divided into two broad categories of either (1) case
series and case reports of NDM-1-producing bacteria, or (2) active
surveillance or environmental surveillance studies of NDM-1-
producing bacteria. When additional information of interest for the
systematic data collection was not in the publication, we
attempted to contact the respective corresponding author to
gather or to discern additional descriptive information for
inclusion in the systematic review. Additional relevant data for
35 cases were obtained from corresponding authors of the original
publications. Subsequent to the initial review of publications, we
conducted a second structured literature search to assure capture
of active laboratory surveillance programs and environmental
surveillance studies of NDM-1-producing pathogens worldwide.
This second literature review was conducted using the same search
limits as the initial PubMed search with the following key search
terms: ‘‘New Delhi metallo-b-lactamase’’, ‘‘NDM-1’’, ‘‘surveillance
study’’, and ‘‘environmental study’’. This search did not yield any
additional NDM-1 surveillance or environmental studies.
2.2. Reported cases: data collection and study deﬁnitions
A case was deﬁned as a patient for whom at least one clinical
isolate of NDM-1-producing bacteria had been isolated, conﬁrmed,
and reported in the published literature. Demographic, clinical,
and microbiological data were systematically collected from the
case reports and case series. The demographic data included age,
gender, and geographic location at the time of the NDM-1
specimen procurement. Exposure to the Indian subcontinent of
south central Asia was deﬁned as ‘yes’ for residence, travel, medical
care, or hospitalization, or ‘no’ for either lack of exposure or
uncertain for exposure. The clinical data included comorbid
conditions, clinical status at hospital discharge or at last follow-
up, recent travel history within 1 year prior to detection of NDM-1,contact with other healthcare facilities, prior medical treatment or
procedures, length of stay at the medical facility abroad, inter-
country transfer, and any local transmission events with known
contact of a travel-associated case. Microbiological data included
the date of specimen collection, the bacterial species harboring
NDM-1, specimen source(s) for both infected and colonized NDM-
1 cases, and the multilocus sequence type (MLST), when available
in the published literature. The MLST is a nucleotide sequence-
based approach for the unambiguous characterization of bacterial
isolates. Additional descriptive and microbiological data, if
available, were also reviewed. Each reported case was categorized
as either infection or presumed colonization. A case infection was
deﬁned as a report of NDM-1-producing bacteria in either (1) blood
or another sterile body ﬂuid specimen, or (2) clinical culture
specimens from potentially non-sterile specimen sources such as
the respiratory tract, wounds, urine, and other sources that were
deemed to be associated with infection by the clinical investigative
team. Cases with infection were further reviewed to determine if
the infected case was also colonized with one or more NDM-1-
producing bacteria, and if conﬁrmed for colonization, the identiﬁed
source(s) of colonization. A case of presumed colonization with
NDM-1-producing bacteria was either (1) asymptomatic, (2)
deemed to be colonized and without infection by the investiga-
tor/authors in either the initial report or follow-up correspon-
dence, or (3) uncertain for infection or colonization by the original
investigators, or if the author did not conﬁrm colonization by
personal communication, the case was categorized as presumed
colonization. Specimens identiﬁed as urinary catheter, skin, and
nose were categorically grouped as ‘other’ sources, and the source
‘wound’ included isolates from pus.
2.3. Laboratory and surveillance studies: data collection and study
deﬁnitions
Identiﬁed surveillance studies for NDM-1-producing bacteria
were assessed for geographic location of the patient at the time the
clinical isolate was procured. Data included specimen source, date
of specimen collection, number of NDM-1 isolates detected for
each case, bacterial species, and when available, the MLST. The
type of surveillance program, target pathogens, and denominator
deﬁnitions were systematically recorded, given the variation in the
laboratory detection methodologies and surveillance programs.
The proportion of NDM-1-producing bacteria reported in each of
these studies was contingent upon the criteria for screening
restricted to either Gram-negative bacteria, Enterobacteriaceae, or
CRE. All data were entered into Microsoft Excel for descriptive
statistics and summary calculations.
3. Results
3.1. Literature review for case reports, case series, and surveillance
studies
The systematic literature review yielded 94 publications with
reports of NDM-1-producing bacteria published in print or online
between January 2008 and July 6, 2011 and limited to humans and
articles in English. Thirty-six publications were case reports or case
series,16,18,21,24,28–59 and nine publications were surveillance
studies;3,4,7,23,60–64 49 publications were excluded. Among exclud-
ed publications was the ﬁrst published case report of NDM-2, a
variant form of NDM, and a report on Acinetobacter baumannii
isolates that lacked pertinent case details.38,65 After review of the
identiﬁed publications and citations, an additional six case
reports,20,66–70 two surveillance studies,17,71 and one Health
Protection Agency report regarding carbapenem resistance and
NDM-119 were included. These publications of NDM-1-producing
Figure 1. Two world maps illustrate (a) the international dissemination of human cases and (b) surveillance isolates with New Delhi metallo-b-lactamase (NDM-1)-
producing Enterobacteriaceae and non-Enterobacteriaceae; data based on publications as of July 6, 2011.
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tional dissemination of case reports and series (Figure 1a) and
surveillance isolates (Figure 1b).
3.2. Case cohort
The ﬁnal cohort comprised 60 reported unique cases with
NDM-1-producing bacteria from independent and overlapping
case reports and case series.16,18,20,21,24,28–59,66–70 Twenty-one
cases (35%) were categorized as infection and 39 cases (65%) were
categorized as presumed colonization with no clinical evidence of
infection (Table 1). There were 29 males (48.3% of the total, with
nine cases unknown for gender), most cases were adults (n = 44,
73.3% of the total; with 11 cases unknown for age), and a
predominance (n = 27, 45%) of case detection in Europe (Table 1).
Exposure to the Indian subcontinent of south central Asia was
reported for 76.2% cases (n = 16) with NDM-1 infection versus
56.4% of cases (n = 22) with colonization. The frequency of reported
case detection increased annually until 2011, with a four-fold
increase in colonized cases between 2008 and 2009 and a four-fold
increase in infected cases between 2009 and 2010. Crude mortality
was higher among persons with infection (23.8%) versus presumed
colonization (10.3%). The NDM-1-producing bacteria associated
with the nine deaths were E. coli (n = 4), K. pneumoniae (n = 2),
Pseudomonas aeruginosa (n = 2), A. baumannii (n = 1), and Provi-
dencia stuartii (n = 1); one case included detection of both NDM-1-
producing E. coli and K. pneumoniae.One or more NDM-1-producing bacteria were reported for
each case, for a total of 84 NDM-1-producing bacterial isolates
reported from the 60 unique cases (Table 2). The majority of
reported NDM-1-producing bacteria (n = 78, 92.9%) were in the
family Enterobacteriaceae, with K. pneumoniae and E. coli
identiﬁed as the most frequently reported bacteria.13,34,47,57,72,73
Urine was the most frequent specimen source for cases with
infection (n = 10, 41.7%) and with colonization (n = 20, 33.3%).
One case from Canada remained colonized and untreated with
NDM-1-producing Morganella morganii 5 months after initial
detection, and another case had Providencia rettgeri urine
colonization 3 months after the initial microbial detection.21
A case from Italy with enteric colonization of NDM-1-producing
E. coli had sustained colonization 10 months after initial
detection, with an interim toe infection attributed to NDM-1-
producing E. coli.34
Seventeen of the 60 cases (28.3%) represented cases with
NDM-1-producing bacteria at more than one body site
(Table 3).16,21,24,31,33,34,36,41,42,47,48,53,54,59 The distribution of these
17 cases included infection (n = 2), colonization (n = 5), and dual
infection and colonization (n = 10).
The MLST characterization was available for 34 of the 84
(40.5%) reported NDM-1-producing bacteria (Table 4). Among
the 20 K. pneumoniae isolates, there were seven different MLST;
sequence type (ST) 14 was the most frequently detected MLST,
with cases from Sweden (n = 1, the index case), Sultanate of
Oman (n = 1), Singapore (n = 1), and Kenya (n = 7).16,45.50 Among
Table 1
Descriptive characteristics of 60 reported cases with NDM-1-producing bacteria
stratiﬁed by infection versus presumed colonization
Descriptive variables Overall
(n = 60)
NDM-1
infection
(n = 21)
NDM-1
colonizationa
(n = 39)
Gender
Male 29 (48.3) 12 (57.1) 17 (43.6)
Female 22 (36.7) 6 (28.6) 16 (41.0)
Unknown 9 (15.0) 3 (14.3) 6 (15.4)
Age (years)
<18 5 (8.3) 4 (19.0) 1 (2.6)
18–65 31 (51.7) 10 (47.6) 21 (53.8)
>65 13 (21.7) 3 (14.3) 10 (25.6)
Unknown 11 (18.3) 4 (19.0) 7 (17.9)
Geographic region
Europe 27 (45.0) 10 (47.6) 17 (43.6)
North America 12 (20.0) 4 (19.0) 8 (20.5)
Asia 11 (18.3) 6 (28.6) 5 (12.8)
Africa 7 (11.7) 0 (0.0) 7 (17.9)
Australia 3 (5.0) 1 (4.8) 2 (5.1)
Indian subcontinent exposureb
Yes 38 (63.3) 16 (76.2) 22 (56.4)
No (unknown/none) 22 (36.7) 5 (23.8) 17 (43.6)
Year of case detection
2007 3 (5.0) 1 (4.8) 2 (5.1)
2008 4 (6.7) 1 (4.8) 3 (7.7)
2009 15 (25.0) 3 (14.3) 12 (30.8)
2010 28 (46.7) 13 (61.9) 15 (38.5)
2011 (through July 6) 3 (5.0) 1 (4.8) 2 (5.1)
Uncertainc 7 (11.7) 2 (9.5) 5 (12.8)
Crude mortalityd 9 (15.0) 5 (23.8) 4 (10.3)
Data are provided as number (%) unless denoted otherwise.
a Presumed colonization if infection not conﬁrmed in report or by corresponding
author.
b Residence, travel, medical care, or hospitalization to the region of south central
Asia, comprising the countries of Pakistan, Bangladesh, India, Sri Lanka, and the
Himalayan states of Nepal and Bhutan.
c Two infected cases and one colonized case detected between March 2009 and
October 2010.
d Specimen sources associated with mortality and infection were blood (n = 3),
urine (n = 1), and wound (n = 1). The specimen sources associated with mortality
and NDM-1 colonization were urine (n = 2), wound (n = 1), and simultaneous wound
and enteric colonization (n = 1).
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representing cases from North America (n = 3), Europe (n = 7),
Australia (n = 1), Japan (n = 1), Norway (n = 1), and Switzerland
(n = 1); 71.4% (n = 10) had presumed case exposure in the Indian
subcontinent.31,33,34,37,41–43,46,48,52,55,58,69,70Table 2
Distribution of 84 NDM-1-producing Enterobacteriaceae (n = 78) and non-Enterobacteriace
specimen source
Bacteria Infection source (n = 24) 
Urine Blood Wound Respb
Klebsiella pneumoniae 5 1 1 2 
Escherichia coli 4 3 5 - 
Providencia spp. - 1 - - 
Citrobacter freundii 1 - - - 
Morganella morganii - - - - 
Enterobacter cloacae - - - - 
Proteus mirabilis - - - - 
Acinetobacter baumannii - 1 - - 
Pseudomonas aeruginosa - - - - 
Total 10 6 6 2 
a Presumed colonization if infection not conﬁrmed in report or by corresponding au
b Resp = respiratory specimen of sputum, bronchoalveolar lavage, or other.
c Other = skin, nose, or urinary catheter.
d Source unknown for one case with Klebsiella pneumoniae presumed colonization.3.3. Laboratory and environmental surveillance for NDM-1-
producing pathogens
During the 3.5-year interval since the index NDM-1 case report,
11 publications and data from the UK Health Protection Agency
were reviewed for additional information related to laboratory-
based or environmental surveillance for NDM-1-producing iso-
lates (Table 5).3,4,7,17,19,23,60–64,71 Variation in detection of NDM-1
was evident, based on the years of surveillance and the
surveillance strategy by type of bacteria or by type of indication
or infection among the seven publication sources from the Indian
subcontinent of central Asia3,17,23,61–64 and the six publication and
data sources from the rest of world region.3,4,7,19,60,71 In the 2006–
2007 SENTRY study, 1.0% (15/1443) of Enterobacteriaceae were
retrospectively identiﬁed as NDM-1-producing bacteria.17 Clinical
isolates with NDM-1 production were collected from New Delhi,
Mumbai, and Pune; no NDM-1-producing bacteria were detected
at any of the other 11 surveillance sites within India.17 In a later
study of Enterobacteriaceae, 1.2% of specimens from Chennai versus
13.1% from Haryana were positive for NDM-1-producing bacteria.3
Among CRE specimens from India, 31–92% tested positive for
NDM-1-producing bacteria.3,17,61,62 An environmental surveil-
lance study conducted in New Delhi detected NDM-1-producing
bacteria in 4% (n = 2/50) of drinking water samples, 30% (n = 51/
171) of seepage samples, and in 0% of the control samples, sewage
efﬂuent.74 As of mid-March 2011 in the UK, the Health Protection
Agency reported 88 isolates of NDM-1-producing CRE.19 A
comprehensive study across China found 0.03% of clinical isolates
(n = 4 of 11 298) tested positive for NDM-1 production; all four
isolates were A. baumannii and three of the patients were
neonates.32
4. Discussion
The current perspective on NDM-1-producing bacteria for
human and environmental health is compounded by interspecies
dispersion, diverse health care practices, and varied antimicrobial
surveillance programs. This systematic literature review provides
three contributions to the current understanding of NDM-1-
producing bacteria related to epidemiology, clinical care, and
implications for international surveillance and preparedness plans.
From an epidemiological perspective, the 60 cases reported in the
literature over a 3.5-year period represent a heterogeneous patient
population with varied multidrug-resistant phenotypes, indicative
of worldwide interspecies dissemination of blaNDM-1 on plas-
mids.51,72,75 NDM-1 plasmids harbor a variety of co-resistanceae (n = 6) detected in 60 cases stratiﬁed by case infection versus colonization and by
Colonization sourcea (n = 60) Total
Urine Stool Respb Wound Otherc
13 8 4 2 4d 40
2 9 4 1 - 28
2 - - - - 3
- - - - - 1
1 1 - 1 - 3
1 - - 1 - 2
- 1 - - - 1
- - 1 1 1 4
1 - - 1 - 2
20 19 9 7 5 84
thor.
Table 3
Descriptive case categorization of 17 reported cases with NDM-1-producing bacteria located at more than one body site and stratiﬁed as case with infection or colonization
with one or two different NDM-1-producing bacteriaa
Case Gram-negative bacteria and infection type Ref.
Single bacterial pathogenb
Infected E. coli urosepsis (blood and urine) 53
E. coli infection (inguinal, perineum, and scrotal wounds) 59
Infected and colonized E. coli blood infection and E. coli respiratory tract colonization 24
K. pneumoniae abdominal wound infection and K. pneumoniae enteric and throat colonization 59
A. baumannii endovascular infection and A. baumannii colonization (skin, tracheal secretions, and wound) 36
K. pneumoniae RTI and K. pneumoniae nasal colonization 41
K. pneumoniae UTI and K. pneumoniae enteric colonization 54
E. coli toe infection and E. coli enteric colonization 34
E. coli blood infection and E. coli urine and sputum colonization 33
Colonized E. coli breast tumor colonization and enteric colonization 46
M. morganii urine and enteric colonization 21
K. pneumoniae decubiti and enteric colonization 59
Two different bacterial pathogensb
Infected and colonized K. pneumoniae UTI and E. coli enteric colonization 48
K. pneumoniae UTI and E. coli enteric colonization 16
K. pneumoniae UTI and E. coli and K. pneumoniae enteric colonization 42
Colonized M. morganii wound and E. cloacae pus colonization 31
K. pneumoniae respiratory colonization and E. coli enteric colonization 31
RTI, respiratory tract infection; UTI, urinary tract infection.
a Presumed colonization if infection not conﬁrmed in publication or by corresponding author.
b NDM-1-producing bacterial pathogen reported in publication or by corresponding author.
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genes, and 16S rRNA methylase genes.75 How diverse sequence
types in bacteria contribute to the dissemination of blaNDM-1
remains a source of ongoing investigation. The MLST data for E. coli
and K. pneumoniae provide an incomplete, yet heterogeneous
global distribution of NDM-1-producing Enterobacteriaceae, which
suggests a non-clonal pattern of dissemination (Table 4). A recent,
noteworthy study from a military hospital in Pakistan, published
after our systematic review end-date, reported enteric prevalenceTable 4
Distribution of multilocus sequence types (MLST) reported in 31 cases with clinical is
Escherichia coli (n = 14)a
Bacteria and MLST sequence type (ST) No. Geographic region of
presumed case expos
K. pneumoniae, n = 20
ST14 10 Sweden and India (1
Sultanate of Oman an
Kenya and North Am
Singapore and Bangla
ST147 4 Australia and India (1
Canada and India (1)
Switzerland and Indi
France and Iraq (1) 
ST11 2 Norway and India (1
Singapore and India 
ST15 1 Belgium and Monten
ST16 1 Canada and India (1)
ST25 1 Switzerland and Nor
ST340 1 Sultanate of Oman an
E. coli, n = 14
ST101 4 Germany and India (
Canada and India (1)
Belgium and Pakistan
Australia and Bangla
ST405 3 Italy and North Amer
Canada and India (1)
ST131 2 France and India (1) 
USA and India (1) 
ST410 2 Switzerland and Nor
Norway and India (1
ST38 1 Japan and India (1) 
ST782 1 Belgium and Monten
ST156 1 Spain and India (1) 
a Total greater than 100% as some cases had more than one clinical isolate sequencerates for NDM-1-producing bacteria of 27.1% for inpatients and
13.8% for outpatients.73 Another recent investigation of NDM-1-
producing carbapenemases in K. pneumoniae from India, Sweden,
and the USA, reported that the most frequently detected MLST
sequence type was ST14, a ﬁnding consistent with what we
identiﬁed for K. pneumoniae (Table 4).76 Notably, the investigators
have suggested that ST14 and ST11 are likely to be important in the
ongoing dissemination of blaNDM-1.
76 These data, together with
environmental surveillance data (Table 5), suggest that there is aolates of NDM-1-producing Klebsiella pneumoniae (n = 20) and NDM-1-producing
 isolate detection and
ure (n)
Detection by year/quarter (Q) Ref.
) 2008 Q1 16
d India (1) 2009 Q1 45
erica (7) 2007 Q2–2009 Q1 50
desh (1) 2010 Q1 39
) 2010 54
 2010 Q3 56
a (1) 2009–2010 48
2010 Q4 49
) 2010 Q2 53
(1) 2010 Q1 39
egro (1) 2010 31
 2010 Q1 42
th America (1) 2009–2010 48
d North America (1) 2009 Q3 45
1) 2009 Q4 69
 2010 42
 (1) 2010 31
desh (1) Not available 70
ica (2) 2009 Q3 34
 2010 Q1 42
2009 Q2 46
2010 Q2 37, 43
th America (1) 2009–2010 48
) 2010 Q1 53
2009 Q2 33, 58
egro (1) 2010 31
Not available 55
d.31,41,48
Table 5
Laboratory and environmental surveillance studies reporting detection of NDM-1-producing bacteria from the Indian subcontinent of south central Asia (n = 7) and the rest of
world regions (n = 6)a
City, study years (Ref.) Source specimenb (n) NDM-1 (n) Bacteria
Geographic region: Indian subcontinent of south central Asiac
14 cities/SENTRY, 2006–2007 (17) Enterobacteriaceae (1443)
Carbapenem-resistant Enterobacteriaceae
(CRE) (39)
Carbapenemase producers (26)
15d Escherichia coli (6);
Enterobacter spp (3);
Klebsiella pneumoniae (6)
Northeast tertiary hospital, August 2009 (63) Surgical site infection (15)
Enterobacteriaceae (11)
3e E. coli; K. pneumoniae;
Enterobacter cloacae
Vascular site infection (8)
Enterobacteriaceae (2)
1e
Mumbai tertiary hospital, August–November
2009 (62)
CRE (24) 22 Klebsiella spp (10);
E. coli (9); Enterobacter
spp (2); Morganella morganii (1)
Chennai, through 2009 (3) Enterobacteriaceae (3521)
CRE (141)
44f E. coli (19); K. pneumoniae (14);
E. cloacae (7); Proteus spp (2);
Citrobacter freundii (1);
Klebsiella oxytoca (1)
Haryana, through 2009 (3) Enterobacteriaceae (198)
CRE (47)
26 K. pneumoniae (26)
Mumbai, through 2009 (3) - 32
Varanasi/NA (3) - 13
Guwahat/NA (3) - 3
Pakistan/multi-city, through 2009 (3) - 25; in eight cities
Mumbai tertiary center, 2009–2010 (61) Carbapenem-resistant Gram-negative
bacilli (310)
Enterobacteriaceae (57)
49 Klebsiella spp (28); E. coli (13);
Enterobacter spp (5); M. morganii
(2); Citrobacter spp (1)
North India tertiary referral hospital and outpatient
departments, February– July 2010 (64)
780 consecutive isolates
(E. coli, K. pneumoniae, Citrobacter spp,
Enterobacter aerogenes, P. mirabilis,
M. morganii)
64 metallo-b-lactamase producers
54g E. coli (30); K. pneumoniae (12);
Citrobacter spp (12)
New Delhi, September–October 2010 (23) Drinking water samples (50) 2 C. freundii; E. coli; K. pneumoniae;
Shigella boydii; Vibrio cholera;
Aeromonas caviae
Seepage samples (171) 51
Efﬂuent samples (70) 0
Geographic region: rest of world
UK, referrals to the ARMRL,
through 2009 (3)
Enterobacteriaceae (NA)
Carbapenemase-producers (73)
37h K. pneumoniae (21); E. coli (7);
Enterobacter spp (5); C. freundii (2);
M. morganii (1); Providencia spp (1)
29 European Union member states, Iceland,
and Norway, 2008–October 2010 (7)
CRE and non-Enterobacteriaceae
producing NDM-1 (cases, not isolates)
87i cases; speciation
for 67 isolates
K. pneumoniae (31); E. coli (16);
Enterobacter spp (4); C. freundii (3);
M. morganii (2); Proteus mirabilis (1);
Acinetobacter baumannii (10)
Europe, Asia, North America, Latin America, the
South Paciﬁc
and the Middle East, 2009 (4)
Ertapenem non-susceptible
Enterobacteriaceae from IAI (235)
1+ carbapenemase gene (66)
33;j only in isolates
from India
K. pneumoniae (18); E. coli (8);
E. cloacae (5); Providencia rettgeri (1);
M. morganii (1)
UK, 2008–March 2011 (19) Enterobacteriaceae conﬁrmed
for NDM-1
88 -
France, February 2004–April 2011 (71) Cases reported to the French Institute
for Public Health Surveillance
9 casesk K. pneumoniae (3); E. coli (3);
C. freundii (1); P. mirabilis (1)k
China—multiple cities across the country,
January 2009–September 2010 (60)
Sequential isolates of Gram-negative
bacilli (A. baumannii, P. aeruginosa,
E. coli, K. pneumoniae) screened
for NDM-1 (11 298)
4l A. baumannii (4)
ARMRL, Antibiotic Resistance Monitoring and Reference Laboratory; IAI, intra-abdominal infection; NA, not available.
a Duplicative reporting of NDM-1 isolates possible; Kumarasamy et al. included surveillance data for south central Asia and the rest of world regions, and is therefore
counted twice.3
b Source specimen column provides details on the underlying population of isolates tested for NDM-1; in many instances the source population narrowed before testing for
NDM-1 occurred, which is demonstrated with multiple rows per study location.
c Pakistan, Bangladesh, India, Sri Lanka, and the Himalayan states of Nepal and Bhutan.
d Specimen source: skin and skin structure infection (n = 7), bloodstream infection (BSI; n = 5), and respiratory tract infection (n = 3); MLST performed only for E. coli with
ST101 (n = 4) and ST167 (n = 2).
e Specimen source: surgical site infection and peripheral vascular access site infections.
f Specimen source: urinary tract infection, pneumonia, and BSI.
g Specimen source: urine (n = 23), endotracheal tube (n = 13), pus (n = 9), umbilical cord tip (n = 2), tissue (n = 2), blood (n = 2), catheter tip (n = 1), sputum (n = 1), and Foley
catheter tip (n = 1).
h Specimen source from 29 patients: urine (n = 15), blood (n = 3), sputum (n = 2), other (n = 6), and unknown (n = 3).
i NDM-1 patients (not isolates) with one or more isolates of Enterobacteriaceae.
j MLST performed in K. pneumoniae and E. coli only; K. pneumoniae typing ST147 (n = 9), ST231 (n = 1), ST11 (n = 1), ST101 (n = 1), ST340 (n = 1), ST391 (n = 1), ST14 (n = 1),
ST20 (n = 1), ST572 (n = 1), and ST571 (n = 1); E. coli typing ST88 (n = 4), ST471 (n = 1), ST2 (n = 1), ST44 (n = 1), and ST501 (n = 1).
k 9 cases from 7 episodes (episode deﬁned as either a sporadic case or >1 case related by an identiﬁed chain of transmission); 8 pathogens were reported for these 7
episodes.
l Specimen source: sputum (n = 2), blood (n = 1), and secretion (n = 1).
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G. Bushnell et al. / International Journal of Infectious Diseases 17 (2013) e325–e333 e331signiﬁcant colonization burden of NDM-1-producing bacteria in
some geographic regions that far exceeds current estimates of case
infections.
From a clinical perspective, our systematic review provides a
selective, yet in-depth summary of 60 reported human cases. The
majority of cases (65%) represented colonization without evidence
of infection, with some cases informative for long-term, asymp-
tomatic colonization. These case presentations have implications
for individual patients, healthcare institutions, and global surveil-
lance. Notably, case detection requires astute clinical care
combined with laboratory detection methods linked to well-
coordinated reporting systems. Prompt case detection facilitates
isolation of patients which, in turn, will optimize low colonization
pressure for NDM-1-producing bacteria in healthcare institutions.
Colonization pressure has been identiﬁed as an independent risk
factor for acquisition of vancomycin-resistant enterococci, methi-
cillin-resistant Staphylococcus aureus, P. aeruginosa, and Clostridium
difﬁcile in deﬁned geographic units over the past 15 years.77–81 In
healthcare settings with source patients infected or colonized with
NDM-1-producing bacteria, infection prevention control strategies
and attention to colonization pressure will be key factors in
minimizing the spread of blaNDM-1 plasmids in deﬁned geographic
units.
The third notable contribution of this review pertains to current
global surveillance and international preparedness plans. Recent
reports and editorial commentaries suggest the need for a
coordinated international monitoring system along with a global
preparedness plan should an outbreak or endemicity of NDM-1-
producing bacterial infections occur.9,13,15,39,72,82–84 Current sur-
veillance systems are limited given the lack of standardized
detection methods for carbapenemases, distinction between
NDM-1 infection and colonization, and data on potential non-
human reservoirs of NDM-1 such as the animal food chain.13
Detection and surveillance of carbapenemase-producing Entero-
bacteriaceae and non-Enterobacteriaceae have become important
for both the selection of appropriate antimicrobial therapy and
implementation of infection control measures. As carbapenemase
production cannot be inferred from a standard antimicrobial
resistance proﬁle, criteria are needed to help determine which
isolates should be suspected and screened for carbapenemase
production and to determine whether phenotypic or genotypic
tests should be adapted for the conﬁrmation of carbapenem
resistance.13 The collective ﬁndings from this systematic review of
human case reports, laboratory surveillance programs, and the
environmental survey portray a complex array of microbial factors
and a global antimicrobial armamentarium that has identiﬁable
gaps for effective treatment paradigms.
We readily acknowledge several limitations associated with
this systematic review. First, incident cases with NDM-1-produc-
ing bacteria were likely underestimated given that systematic
mandatory reporting of CRE and other highly-resistant Entero-
bacteriaceae did not exist during the study period. Second,
ascertainment bias in information and measurement, as well as
reporting biases, were inherent in the study design given the
recognized gaps in available information, lack of standardized
microbial diagnostics, and resources available to characterize
NDM-1-producing bacteria in resource-limited settings and in all
geographic regions. Third, the association between exposure
within the Indian subcontinent and NDM-1-producing bacteria
may or may not be overestimated, as publication bias may be
bidirectional and patients who reported exposure to the Indian
subcontinent were perhaps more likely to be screened for NDM-1-
producing bacteria. Fourth, the maps that portray the location of
publications for cases and surveillance studies of NDM-1-produc-
ing bacteria (Figure 1) likely underestimate global spread.
Nonetheless, they provide a comparative benchmark with thereports of K. pneumoniae carbapenemases (KPC) and other evolving
carbapenemases.85 The ﬁrst KPC was detected in a 1996 clinical
isolate from North Carolina and there are now nine KPC
variants.85,86 Fifth, as deﬁned by our study and reported in our
results, this review was restricted to NDM-1-producing bacteria
and did not include subsequently characterized variant forms of
NDM. Lastly, it is likely that case infections relative to case
colonization are underestimated based on our study deﬁnitions
and follow-up on clinical case data with corresponding authors.
Nonetheless, epidemiological studies utilizing well-established
base populations and a clear and standardized disease deﬁnition
are optimal methods for estimating the incidence and prevalence
of infections and colonization with NDM-1-producing bacteria.
This systematic literature review summarizes the epidemiolo-
gy, clinical cases, and surveillance studies of NDM-1-producing
bacteria over the 3.5-year interval since the initial characterization
of a urinary isolate of NDM-1-producing K. pneumoniae. A global
distribution of NDM-1-producing Enterobacteriaceae and non-
Enterobacteriaceae is evident, linked to both human infection and
colonization, and there are recognized implications for antimicro-
bial drug development programs and population health.3,8,13–15
Overall, the ﬁndings in this systematic review, compounded by the
complexity of the genetic plasticity of blaNDM-1, support the need
for astute clinical case recognition, reliable laboratory detection
methods, secure infection control practices, and well-integrated
surveillance systems.
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